Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study Baker, M., Chalabi, Y., Genovese, M., Taylor, P., Schlichting, D., Beattie, S., Macias, W., Keystone, E. J RHEUMATOL PUBL CO. 2014: 1505

View details for Web of Science ID 000338923700160